Ravgen
Ravgen is a Columbia, Maryland-based biotechnology company that provides non-invasive prenatal diagnostic tests (paternity, Down syndrome, and single-gene disorders) from a maternal blood sample, serving pregnant women and referring physicians in the U.S. and Canada.
- Company typePrivate
- Founded2000
- HeadquartersColumbia, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Ravgen does
Ravgen is a privately held biotechnology company headquartered in Columbia, Maryland, founded in September 2000 by Dr. Ravinder Dhallan. The company develops non-invasive prenatal diagnostic tests that analyze fetal DNA isolated from a maternal blood sample, eliminating the miscarriage risk associated with invasive procedures such as amniocentesis and chorionic villus sampling. Its core scientific contribution is a formaldehyde-based fixative method that raises fetal DNA to approximately 25% of total cell-free DNA in maternal plasma, combined with a non-hybridization-based DNA sequencing approach. The product suite includes non-invasive prenatal paternity DNA testing (NIPT), prenatal Down syndrome (trisomy 21) detection, and single-gene disorder screening for conditions such as cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and the Eastern European Jewish panel.
Ravgen's commercial offering is built around a CLIA-certified, CAP-accredited laboratory operating from a single site at 9241 Rumsey Rd, Columbia, MD, supplemented by a national network of partner collection sites that allow patients to provide samples locally in the U.S. (and Canada). The company goes to market via direct-to-consumer inquiries, physician referrals, and a partnership channel inviting other laboratories to resell its paternity services. Per-test pricing for the paternity test is approximately $1,600 — comparable to amniocentesis — with payment plans available.
Commercially, Ravgen has remained very small: cumulative disclosed throughput on the paternity test is '200+ women' as of the most recent reporting, headcount is in the 1–10 range, and capital raised is limited to approximately $1.09M in 2012 and a 2021 Regulation D debt offering of up to $3.5M (~$2.48M sold). The company has historically relied on peer-reviewed publications in JAMA (2004), The Lancet (2007), and the New England Journal of Medicine (2012), plus earned media coverage in outlets such as the New York Times, BBC, Reuters, CNN, and MIT Technology Review, to build scientific credibility and demand, rather than enterprise sales infrastructure.
Ravgen firmographics
Firmographics- Name
- Ravgen
- Legal name
- RAVGEN, INC.
- Website
- https://ravgen.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ravgen is a Columbia, Maryland-based biotechnology company that provides non-invasive prenatal diagnostic tests (paternity, Down syndrome, and single-gene disorders) from a maternal blood sample, serving pregnant women and referring physicians in the U.S. and Canada.
- Ownership category
- akta.pro rank
Ravgen industry classification
Industry- Product category
- Non-Invasive Prenatal Diagnostic Testing
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where Ravgen is headquartered
LocationHeadquarters
- HQ city
- Columbia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ravgen business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Prenatal Diagnostic Testing Services: Ravgen generates revenue through providing non-invasive prenatal diagnostic testing services directly to patients and healthcare providers. Services include prenatal paternity testing, single gene disorder testing, and Down syndrome testing. The company collects samples through their main laboratory and partner collection sites across the United States.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Prenatal Paternity Test |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Ravgen product offering
Product offeringCore offering
Ravgen is a CLIA-certified, CAP-accredited biotechnology laboratory that performs non-invasive prenatal diagnostic tests from a routine maternal blood draw. Its core services are Non-Invasive Prenatal Paternity DNA Testing, Prenatal Down Syndrome Testing, and Single Gene Disorder Testing for conditions such as cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and Eastern European Jewish panel disorders. Tests can be performed as early as 5 weeks gestation with over 99% accuracy for paternity, eliminating the miscarriage risk of invasive procedures like amniocentesis or chorionic villus sampling.
Product overview
Ravgen offers a suite of non-invasive prenatal diagnostic tests built around their proprietary fetal DNA enrichment technology, which increases the percentage of fetal DNA in maternal blood samples. The main products include Non-Invasive Prenatal Paternity DNA Testing (NIPT), Prenatal Down Syndrome Testing, and Single Gene Disorder Testing for conditions such as cystic fibrosis, sickle cell anemia, and the Eastern European Jewish panel. All tests require only a routine blood draw from the pregnant mother, eliminating the miscarriage risk associated with invasive procedures like amniocentesis or chorionic villus sampling. Testing can be performed as early as 5 weeks gestation.
Differentiator
Problem solved
Functional benefit
Products and services
- Non-Invasive Prenatal Paternity DNA Testing (NIPT) Non-invasive prenatal paternity DNA test that determines fetal DNA matching with potential fathers from a safe blood draw from the mother and a buccal swab from the alleged father; can be performed as early as 5 weeks gestation with over 99% accuracy. Used by pregnant women, legal professionals, and physicians for paternity confirmation during pregnancy.
- Prenatal Down Syndrome Testing Non-invasive prenatal test that detects the presence of all or part of a third copy of chromosome 21 (Down syndrome) from a maternal blood sample, using Ravgen's proprietary fetal DNA enrichment technology. Targets pregnant women seeking chromosomal abnormality screening without invasive procedures.
- Single Gene Disorder Testing Non-invasive prenatal genetic testing for single gene disorders such as cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and the Eastern European Jewish panel, performed from a maternal blood sample. Intended for pregnant women and couples who are carriers of recessive single gene disorders and need early, safe diagnosis.
Quantifiable outcome
- Over 99% accuracy in prenatal paternity testing
- +3 more outcomes
Companies that use Ravgen
Customer profileSegments3 records
Ideal customer profiles4 records
Ravgen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ravgen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Collection Sites Across the United StatescoreRavgen partners with collection sites throughout the United States to facilitate sample collection, allowing patients to visit nearby locations rather than traveling to the main laboratory in Columbia, MD. This expands service accessibility nationwide.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Ravgen competitors and assessment
Company assessmentDirect peers
- Myriad Genetics: Myriad operates a women's health segment including prenatal screening (Foresight) and hereditary cancer testing. Its product mix, sales model, and clinical lab structure make it a direct analog for Ravgen's positioning in reproductive and germline genetic testing.
- Invitae: Invitae is a genetic testing company with a reproductive health segment that includes carrier screening and NIPT-adjacent offerings. It is comparable to Ravgen as a technology-forward genetic testing provider serving OB/GYNs and reproductive medicine.
- Sema4: Sema4 operates a clinical genomic testing platform with reproductive and women's health offerings. It competes with Ravgen in delivering genetic and prenatal test results to physicians and patients, with a comparable specialty-laboratory positioning.
- Natera: Natera is a publicly traded genetic testing company with one of the leading commercial NIPT franchises (Panorama) and a broad reproductive health portfolio. It is the most directly comparable scaled competitor to Ravgen in non-invasive prenatal testing.
- Progenity: Progenity developed NIPT and reproductive health diagnostics with proprietary molecular methods, competing for the same OB/GYN channel as Ravgen. It is a direct product-adjacent peer in prenatal genetic testing.
Broad incumbents
- Illumina: Illumina supplies the next-generation sequencing platforms that underpin nearly all NIPT workflows, including Ravgen's non-hybridization method. It is a foundational enabling incumbent whose technology choices shape the competitive landscape for specialty NIPT labs.
- Quest Diagnostics: Quest is one of the largest US clinical laboratory networks and offers QNatal Advanced, a non-invasive prenatal screening test. It overlaps with Ravgen on NIPT but operates as a broad clinical reference lab rather than a specialist.
- Labcorp (Integrated Genetics / Sequenom heritage): Labcorp runs a national clinical lab network that includes prenatal screening services acquired via its Sequenom/MaterniT21 franchise. It competes broadly with Ravgen on Down syndrome and reproductive genetic screening as part of a much larger diagnostics menu.
Emerging players
- NeoGenomics: NeoGenomics specializes in oncology-focused genetic and molecular testing but has expanded into reproductive health through its NeoGenDay offering. It is an emerging adjacent player rather than a head-to-head NIPT competitor.
- GeneDx (Sema4-owned subsidiary): GeneDx provides clinical exome and genome sequencing with reproductive and rare disease panels, overlapping with Ravgen's single-gene disorder and carrier testing use cases. It is an emerging clinical genomics peer competing for similar specialty referral volume.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Ravgen social profiles
Digital presenceRavgen compliance and trust
Trust signalCompliance2 records
Ravgen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ravgen leadership team
Management profileNumber of profiles
Profiles1 record
Ravgen funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ravgen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ravgen
What does Ravgen do?
Ravgen is a CLIA-certified, CAP-accredited biotechnology laboratory that performs non-invasive prenatal diagnostic tests from a routine maternal blood draw. Its core services are Non-Invasive Prenatal Paternity DNA Testing, Prenatal Down Syndrome Testing, and Single Gene Disorder Testing for conditions such as cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and Eastern European Jewish panel disorders. Tests can be performed as early as 5 weeks gestation with over 99% accuracy for paternity, eliminating the miscarriage risk of invasive procedures like amniocentesis or chorionic villus sampling.
Is Ravgen a public or private company?
Ravgen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ravgen founded?
Ravgen was founded in 2000. It employs 1 to 10 people.
Where is Ravgen based?
Ravgen is headquartered in Columbia, United States, in the North America region.
How does Ravgen make money?
One revenue line is on record: prenatal Diagnostic Testing Services.
Who are Ravgen's main competitors?
Direct peers on record are Myriad Genetics, Invitae, Sema4, Natera and Progenity. Broad incumbents are Illumina, Quest Diagnostics and Labcorp (Integrated Genetics / Sequenom heritage). Emerging players are NeoGenomics and GeneDx (Sema4-owned subsidiary).
Does Ravgen have an API?
No public API is recorded for Ravgen.
What industry is Ravgen in?
Ravgen's product category is Non-Invasive Prenatal Diagnostic Testing. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 8071.